MRSN — Mersana Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $356.63m
- $172.98m
- $36.86m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 99.8 | 255 | 178 | 281 | 209 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0 | — | — | 30 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 101 | 259 | 189 | 319 | 214 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4.76 | 12.7 | 14.9 | 14.5 | 11.5 |
Other Long Term Assets | |||||
Total Assets | 108 | 273 | 206 | 334 | 226 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 24.1 | 30 | 47.5 | 91.5 | 63.6 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 29.2 | 45.3 | 84.4 | 242 | 189 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 78.3 | 228 | 122 | 92.1 | 36.9 |
Total Liabilities & Shareholders' Equity | 108 | 273 | 206 | 334 | 226 |
Total Common Shares Outstanding |